APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neurodegenerative Disease Market Analysis and Forecast 2026-2032

19 December 2025202 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neurodegenerative Disease is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neurodegenerative Disease is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neurodegenerative Disease is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neurodegenerative Disease is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neurodegenerative Disease include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neurodegenerative Disease, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neurodegenerative Disease, also provides the revenue of main regions and countries. Of the upcoming market potential for Neurodegenerative Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Disease revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neurodegenerative Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neurodegenerative Disease revenue, projected growth trends, production technology, application and end-user industry.

Neurodegenerative Disease Segment by Company

Biogen Idec

Boehringer Ingelheim

Merck Serono

UCB

BORA PHARMACEUTICALS

Dongcheng Biochemicals

Ark Pharmaceutical

GlaxoSmithKline

Haisco Pharmaceutical

Hisun Pharmaceutical

Huahai Pharmaceutical

Pfizer

Jingxin Pharmaceutical

Kanghong Pharmaceutical

Livzon Pharmaceutical

Luye Pharma

Novartis

Sanofi

TEVA

Neurodegenerative Disease Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Disease Segment by Application

Alzheimer’s Disease

Huntington Disease

Amyotrophic Lateral Sclerosis

Parkinson’s Disease

Neurodegenerative Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neurodegenerative Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neurodegenerative Disease company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NMDA Major Player Table 3. SSRIs Major Player Table 4. Dopamine Inhibitors Major Player Table 5. Global Neurodegenerative Disease Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Alzheimer’s Disease Major Player Table 7. Huntington Disease Major Player Table 8. Amyotrophic Lateral Sclerosis Major Player Table 9. Parkinson’s Disease Major Player Table 10. Neurodegenerative Disease Industry Trends Table 11. Neurodegenerative Disease Industry Drivers Table 12. Neurodegenerative Disease Industry Opportunities and Challenges Table 13. Neurodegenerative Disease Industry Restraints Table 14. Global Neurodegenerative Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Neurodegenerative Disease Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Neurodegenerative Disease Market Share by Region (2021-2026) Table 17. Global Neurodegenerative Disease Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Neurodegenerative Disease Market Share by Region (2027-2032) Table 19. Global Neurodegenerative Disease Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Neurodegenerative Disease Revenue Market Share by Players (2021-2026) Table 21. Global Neurodegenerative Disease Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Neurodegenerative Disease Key Players Headquarters & Area Served Table 23. Global Neurodegenerative Disease Players, Product Type & Application Table 24. Global Neurodegenerative Disease Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Neurodegenerative Disease by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Neurodegenerative Disease Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Neurodegenerative Disease Revenue Market Share by Type (2021-2026) Table 31. Global Neurodegenerative Disease Revenue Market Share by Type (2027-2032) Table 32. Global Neurodegenerative Disease Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Neurodegenerative Disease Revenue Market Share by Application (2021-2026) Table 36. Global Neurodegenerative Disease Revenue Market Share by Application (2027-2032) Table 37. Biogen Idec Company Information Table 38. Biogen Idec Business Overview Table 39. Biogen Idec Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Biogen Idec Neurodegenerative Disease Product Portfolio Table 41. Biogen Idec Recent Development Table 42. Boehringer Ingelheim Company Information Table 43. Boehringer Ingelheim Business Overview Table 44. Boehringer Ingelheim Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Boehringer Ingelheim Neurodegenerative Disease Product Portfolio Table 46. Boehringer Ingelheim Recent Development Table 47. Merck Serono Company Information Table 48. Merck Serono Business Overview Table 49. Merck Serono Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Merck Serono Neurodegenerative Disease Product Portfolio Table 51. Merck Serono Recent Development Table 52. UCB Company Information Table 53. UCB Business Overview Table 54. UCB Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. UCB Neurodegenerative Disease Product Portfolio Table 56. UCB Recent Development Table 57. BORA PHARMACEUTICALS Company Information Table 58. BORA PHARMACEUTICALS Business Overview Table 59. BORA PHARMACEUTICALS Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio Table 61. BORA PHARMACEUTICALS Recent Development Table 62. Dongcheng Biochemicals Company Information Table 63. Dongcheng Biochemicals Business Overview Table 64. Dongcheng Biochemicals Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio Table 66. Dongcheng Biochemicals Recent Development Table 67. Ark Pharmaceutical Company Information Table 68. Ark Pharmaceutical Business Overview Table 69. Ark Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Ark Pharmaceutical Neurodegenerative Disease Product Portfolio Table 71. Ark Pharmaceutical Recent Development Table 72. GlaxoSmithKline Company Information Table 73. GlaxoSmithKline Business Overview Table 74. GlaxoSmithKline Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. GlaxoSmithKline Neurodegenerative Disease Product Portfolio Table 76. GlaxoSmithKline Recent Development Table 77. Haisco Pharmaceutical Company Information Table 78. Haisco Pharmaceutical Business Overview Table 79. Haisco Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio Table 81. Haisco Pharmaceutical Recent Development Table 82. Hisun Pharmaceutical Company Information Table 83. Hisun Pharmaceutical Business Overview Table 84. Hisun Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio Table 86. Hisun Pharmaceutical Recent Development Table 87. Huahai Pharmaceutical Company Information Table 88. Huahai Pharmaceutical Business Overview Table 89. Huahai Pharmaceutical Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio Table 91. Huahai Pharmaceutical Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Pfizer Neurodegenerative Disease Product Portfolio Table 96. Pfizer Recent Development Table 97. Jingxin Pharmaceutical Company Information Table 98. Jingxin Pharmaceutical Business Overview Table 99. Jingxin Pharmaceutical Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio Table 101. Jingxin Pharmaceutical Recent Development Table 102. Kanghong Pharmaceutical Company Information Table 103. Kanghong Pharmaceutical Business Overview Table 104. Kanghong Pharmaceutical Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio Table 106. Kanghong Pharmaceutical Recent Development Table 107. Livzon Pharmaceutical Company Information Table 108. Livzon Pharmaceutical Business Overview Table 109. Livzon Pharmaceutical Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio Table 111. Livzon Pharmaceutical Recent Development Table 112. Luye Pharma Company Information Table 113. Luye Pharma Business Overview Table 114. Luye Pharma Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Luye Pharma Neurodegenerative Disease Product Portfolio Table 116. Luye Pharma Recent Development Table 117. Novartis Company Information Table 118. Novartis Business Overview Table 119. Novartis Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novartis Neurodegenerative Disease Product Portfolio Table 121. Novartis Recent Development Table 122. Sanofi Company Information Table 123. Sanofi Business Overview Table 124. Sanofi Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Sanofi Neurodegenerative Disease Product Portfolio Table 126. Sanofi Recent Development Table 127. TEVA Company Information Table 128. TEVA Business Overview Table 129. TEVA Neurodegenerative Disease Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. TEVA Neurodegenerative Disease Product Portfolio Table 131. TEVA Recent Development Table 132. North America Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 133. North America Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 134. North America Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 135. North America Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 136. North America Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Neurodegenerative Disease Revenue by Country (2021-2026) & (US$ Million) Table 138. North America Neurodegenerative Disease Revenue by Country (US$ Million) & (2027-2032) Table 139. Europe Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Europe Neurodegenerative Disease Revenue by Country (2021-2026) & (US$ Million) Table 145. Europe Neurodegenerative Disease Revenue by Country (US$ Million) & (2027-2032) Table 146. China Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 147. China Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 148. China Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 149. China Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 150. Asia Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 151. Asia Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 152. Asia Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Neurodegenerative Disease Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Asia Neurodegenerative Disease Revenue by Region (US$ Million) & (2021-2026) Table 156. Asia Neurodegenerative Disease Revenue by Region (US$ Million) & (2027-2032) Table 157. SAMEA Neurodegenerative Disease Revenue by Type (2021-2026) & (US$ Million) Table 158. SAMEA Neurodegenerative Disease Revenue by Type (2027-2032) & (US$ Million) Table 159. SAMEA Neurodegenerative Disease Revenue by Application (2021-2026) & (US$ Million) Table 160. SAMEA Neurodegenerative Disease Revenue by Application (2027-2032) & (US$ Million) Table 161. SAMEA Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. SAMEA Neurodegenerative Disease Revenue by Country (2021-2026) & (US$ Million) Table 163. SAMEA Neurodegenerative Disease Revenue by Country (US$ Million) & (2027-2032) Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Neurodegenerative Disease Image Figure 2. Global Neurodegenerative Disease Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Disease Market Size Share 2021 VS 2025 VS 2032 Figure 4. NMDA Image Figure 5. SSRIs Image Figure 6. Dopamine Inhibitors Image Figure 7. Global Neurodegenerative Disease Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neurodegenerative Disease Market Size Share 2021 VS 2025 VS 2032 Figure 9. Alzheimer’s Disease Image Figure 10. Huntington Disease Image Figure 11. Amyotrophic Lateral Sclerosis Image Figure 12. Parkinson’s Disease Image Figure 13. Global Neurodegenerative Disease Market Size (US$ Million) & (2021-2032) Figure 14. Global Neurodegenerative Disease Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Neurodegenerative Disease Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Neurodegenerative Disease Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Neurodegenerative Disease Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Neurodegenerative Disease Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Neurodegenerative Disease Revenue Market Share by Type (2021-2032) Figure 21. Global Neurodegenerative Disease Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Neurodegenerative Disease Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Neurodegenerative Disease Revenue Market Share by Application (2021-2032) Figure 24. North America Neurodegenerative Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Neurodegenerative Disease Revenue Share by Type (2021-2032) Figure 26. North America Neurodegenerative Disease Revenue Share by Application (2021-2032) Figure 27. North America Neurodegenerative Disease Revenue Share by Country (2021-2032) Figure 28. United States Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Neurodegenerative Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Neurodegenerative Disease Revenue Share by Type (2021-2032) Figure 33. Europe Neurodegenerative Disease Revenue Share by Application (2021-2032) Figure 34. Europe Neurodegenerative Disease Revenue Share by Country (2021-2032) Figure 35. Germany Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Neurodegenerative Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Neurodegenerative Disease Revenue Share by Type (2021-2032) Figure 45. China Neurodegenerative Disease Revenue Share by Application (2021-2032) Figure 46. Asia Neurodegenerative Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Neurodegenerative Disease Revenue Share by Type (2021-2032) Figure 48. Asia Neurodegenerative Disease Revenue Share by Application (2021-2032) Figure 49. Asia Neurodegenerative Disease Revenue Share by Region (2021-2032) Figure 50. Japan Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Neurodegenerative Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Neurodegenerative Disease Revenue Share by Type (2021-2032) Figure 58. SAMEA Neurodegenerative Disease Revenue Share by Application (2021-2032) Figure 59. SAMEA Neurodegenerative Disease Revenue Share by Country (2021-2032) Figure 60. Brazil Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Neurodegenerative Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Alzheimer’s Disease
  • Huntington Disease
  • Amyotrophic Lateral Sclerosis
  • Parkinson’s Disease
Companies covered
  • Biogen Idec
  • Boehringer Ingelheim
  • Merck Serono
  • UCB
  • BORA PHARMACEUTICALS
  • Dongcheng Biochemicals
  • Ark Pharmaceutical
  • GlaxoSmithKline
  • Haisco Pharmaceutical
  • Hisun Pharmaceutical
  • Huahai Pharmaceutical
  • Pfizer
  • Jingxin Pharmaceutical
  • Kanghong Pharmaceutical
  • Livzon Pharmaceutical
  • Luye Pharma
  • Novartis
  • Sanofi
  • TEVA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neurodegenerative Disease Market by Type
  3. 1.2.1 Global Neurodegenerative Disease Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NMDA
  5. 1.2.3 SSRIs
  6. 1.2.4 Dopamine Inhibitors
  7. 1.3 Neurodegenerative Disease Market by Application
  8. 1.3.1 Global Neurodegenerative Disease Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Alzheimer’s Disease
  10. 1.3.3 Huntington Disease
  11. 1.3.4 Amyotrophic Lateral Sclerosis
  12. 1.3.5 Parkinson’s Disease
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neurodegenerative Disease Market Dynamics
  1. 2.1 Neurodegenerative Disease Industry Trends
  2. 2.2 Neurodegenerative Disease Industry Drivers
  3. 2.3 Neurodegenerative Disease Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neurodegenerative Disease Market Perspective (2021-2032)
  2. 3.2 Global Neurodegenerative Disease Growth Trends by Region
  3. 3.2.1 Global Neurodegenerative Disease Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neurodegenerative Disease Market Size by Region (2021-2026)
  5. 3.2.3 Global Neurodegenerative Disease Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neurodegenerative Disease Revenue by Players
  2. 4.1.1 Global Neurodegenerative Disease Revenue by Players (2021-2026)
  3. 4.1.2 Global Neurodegenerative Disease Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neurodegenerative Disease Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neurodegenerative Disease Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neurodegenerative Disease Key Players Headquarters & Area Served
  7. 4.4 Global Neurodegenerative Disease Players, Product Type & Application
  8. 4.5 Global Neurodegenerative Disease Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neurodegenerative Disease Market CR5 and HHI
  11. 4.6.3 2025 Neurodegenerative Disease Tier 1, Tier 2, and Tier 3
5 Neurodegenerative Disease Market Size by Type
  1. 5.1 Global Neurodegenerative Disease Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 5.3 Global Neurodegenerative Disease Revenue Market Share by Type (2021-2032)
6 Neurodegenerative Disease Market Size by Application
  1. 6.1 Global Neurodegenerative Disease Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neurodegenerative Disease Revenue by Application (2021-2032)
  3. 6.3 Global Neurodegenerative Disease Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen Idec
  2. 7.1.1 Biogen Idec Company Information
  3. 7.1.2 Biogen Idec Business Overview
  4. 7.1.3 Biogen Idec Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
  6. 7.1.5 Biogen Idec Recent Developments
  7. 7.2 Boehringer Ingelheim
  8. 7.2.1 Boehringer Ingelheim Company Information
  9. 7.2.2 Boehringer Ingelheim Business Overview
  10. 7.2.3 Boehringer Ingelheim Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
  12. 7.2.5 Boehringer Ingelheim Recent Developments
  13. 7.3 Merck Serono
  14. 7.3.1 Merck Serono Company Information
  15. 7.3.2 Merck Serono Business Overview
  16. 7.3.3 Merck Serono Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
  18. 7.3.5 Merck Serono Recent Developments
  19. 7.4 UCB
  20. 7.4.1 UCB Company Information
  21. 7.4.2 UCB Business Overview
  22. 7.4.3 UCB Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  23. 7.4.4 UCB Neurodegenerative Disease Product Portfolio
  24. 7.4.5 UCB Recent Developments
  25. 7.5 BORA PHARMACEUTICALS
  26. 7.5.1 BORA PHARMACEUTICALS Company Information
  27. 7.5.2 BORA PHARMACEUTICALS Business Overview
  28. 7.5.3 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  29. 7.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
  30. 7.5.5 BORA PHARMACEUTICALS Recent Developments
  31. 7.6 Dongcheng Biochemicals
  32. 7.6.1 Dongcheng Biochemicals Company Information
  33. 7.6.2 Dongcheng Biochemicals Business Overview
  34. 7.6.3 Dongcheng Biochemicals Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
  36. 7.6.5 Dongcheng Biochemicals Recent Developments
  37. 7.7 Ark Pharmaceutical
  38. 7.7.1 Ark Pharmaceutical Company Information
  39. 7.7.2 Ark Pharmaceutical Business Overview
  40. 7.7.3 Ark Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
  42. 7.7.5 Ark Pharmaceutical Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 Haisco Pharmaceutical
  50. 7.9.1 Haisco Pharmaceutical Company Information
  51. 7.9.2 Haisco Pharmaceutical Business Overview
  52. 7.9.3 Haisco Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
  54. 7.9.5 Haisco Pharmaceutical Recent Developments
  55. 7.10 Hisun Pharmaceutical
  56. 7.10.1 Hisun Pharmaceutical Company Information
  57. 7.10.2 Hisun Pharmaceutical Business Overview
  58. 7.10.3 Hisun Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
  60. 7.10.5 Hisun Pharmaceutical Recent Developments
  61. 7.11 Huahai Pharmaceutical
  62. 7.11.1 Huahai Pharmaceutical Company Information
  63. 7.11.2 Huahai Pharmaceutical Business Overview
  64. 7.11.3 Huahai Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
  66. 7.11.5 Huahai Pharmaceutical Recent Developments
  67. 7.12 Pfizer
  68. 7.12.1 Pfizer Company Information
  69. 7.12.2 Pfizer Business Overview
  70. 7.12.3 Pfizer Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Pfizer Neurodegenerative Disease Product Portfolio
  72. 7.12.5 Pfizer Recent Developments
  73. 7.13 Jingxin Pharmaceutical
  74. 7.13.1 Jingxin Pharmaceutical Company Information
  75. 7.13.2 Jingxin Pharmaceutical Business Overview
  76. 7.13.3 Jingxin Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
  78. 7.13.5 Jingxin Pharmaceutical Recent Developments
  79. 7.14 Kanghong Pharmaceutical
  80. 7.14.1 Kanghong Pharmaceutical Company Information
  81. 7.14.2 Kanghong Pharmaceutical Business Overview
  82. 7.14.3 Kanghong Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
  84. 7.14.5 Kanghong Pharmaceutical Recent Developments
  85. 7.15 Livzon Pharmaceutical
  86. 7.15.1 Livzon Pharmaceutical Company Information
  87. 7.15.2 Livzon Pharmaceutical Business Overview
  88. 7.15.3 Livzon Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
  90. 7.15.5 Livzon Pharmaceutical Recent Developments
  91. 7.16 Luye Pharma
  92. 7.16.1 Luye Pharma Company Information
  93. 7.16.2 Luye Pharma Business Overview
  94. 7.16.3 Luye Pharma Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
  96. 7.16.5 Luye Pharma Recent Developments
  97. 7.17 Novartis
  98. 7.17.1 Novartis Company Information
  99. 7.17.2 Novartis Business Overview
  100. 7.17.3 Novartis Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Novartis Neurodegenerative Disease Product Portfolio
  102. 7.17.5 Novartis Recent Developments
  103. 7.18 Sanofi
  104. 7.18.1 Sanofi Company Information
  105. 7.18.2 Sanofi Business Overview
  106. 7.18.3 Sanofi Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Sanofi Neurodegenerative Disease Product Portfolio
  108. 7.18.5 Sanofi Recent Developments
  109. 7.19 TEVA
  110. 7.19.1 TEVA Company Information
  111. 7.19.2 TEVA Business Overview
  112. 7.19.3 TEVA Neurodegenerative Disease Revenue and Gross Margin (2021-2026)
  113. 7.19.4 TEVA Neurodegenerative Disease Product Portfolio
  114. 7.19.5 TEVA Recent Developments
8 North America
  1. 8.1 North America Neurodegenerative Disease Revenue (2021-2032)
  2. 8.2 North America Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 8.2.1 North America Neurodegenerative Disease Revenue by Type (2021-2026)
  4. 8.2.2 North America Neurodegenerative Disease Revenue by Type (2027-2032)
  5. 8.3 North America Neurodegenerative Disease Revenue Share by Type (2021-2032)
  6. 8.4 North America Neurodegenerative Disease Revenue by Application (2021-2032)
  7. 8.4.1 North America Neurodegenerative Disease Revenue by Application (2021-2026)
  8. 8.4.2 North America Neurodegenerative Disease Revenue by Application (2027-2032)
  9. 8.5 North America Neurodegenerative Disease Revenue Share by Application (2021-2032)
  10. 8.6 North America Neurodegenerative Disease Revenue by Country
  11. 8.6.1 North America Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neurodegenerative Disease Revenue by Country (2021-2026)
  13. 8.6.3 North America Neurodegenerative Disease Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neurodegenerative Disease Revenue (2021-2032)
  2. 9.2 Europe Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neurodegenerative Disease Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neurodegenerative Disease Revenue by Type (2027-2032)
  5. 9.3 Europe Neurodegenerative Disease Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neurodegenerative Disease Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neurodegenerative Disease Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neurodegenerative Disease Revenue by Application (2027-2032)
  9. 9.5 Europe Neurodegenerative Disease Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neurodegenerative Disease Revenue by Country
  11. 9.6.1 Europe Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neurodegenerative Disease Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neurodegenerative Disease Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Neurodegenerative Disease Revenue (2021-2032)
  2. 10.2 China Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 10.2.1 China Neurodegenerative Disease Revenue by Type (2021-2026)
  4. 10.2.2 China Neurodegenerative Disease Revenue by Type (2027-2032)
  5. 10.3 China Neurodegenerative Disease Revenue Share by Type (2021-2032)
  6. 10.4 China Neurodegenerative Disease Revenue by Application (2021-2032)
  7. 10.4.1 China Neurodegenerative Disease Revenue by Application (2021-2026)
  8. 10.4.2 China Neurodegenerative Disease Revenue by Application (2027-2032)
  9. 10.5 China Neurodegenerative Disease Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neurodegenerative Disease Revenue (2021-2032)
  2. 11.2 Asia Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neurodegenerative Disease Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neurodegenerative Disease Revenue by Type (2027-2032)
  5. 11.3 Asia Neurodegenerative Disease Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neurodegenerative Disease Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neurodegenerative Disease Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neurodegenerative Disease Revenue by Application (2027-2032)
  9. 11.5 Asia Neurodegenerative Disease Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neurodegenerative Disease Revenue by Country
  11. 11.6.1 Asia Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neurodegenerative Disease Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neurodegenerative Disease Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neurodegenerative Disease Revenue (2021-2032)
  2. 12.2 SAMEA Neurodegenerative Disease Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neurodegenerative Disease Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neurodegenerative Disease Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neurodegenerative Disease Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neurodegenerative Disease Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neurodegenerative Disease Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neurodegenerative Disease Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neurodegenerative Disease Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neurodegenerative Disease Revenue by Country
  11. 12.6.1 SAMEA Neurodegenerative Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neurodegenerative Disease Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neurodegenerative Disease Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst